Scholar Rock Q3 2023 Earnings Report
Key Takeaways
Scholar Rock reported a net loss of $42.4 million for Q3 2023, with no revenue recorded. The company completed enrollment for the Phase 3 SAPPHIRE trial and presented data supporting SRK-181. A $98 million public offering was completed, extending the cash runway into the second half of 2025.
Completed enrollment for pivotal Phase 3 SAPPHIRE trial evaluating apitegromab.
Expanded into cardiometabolic disorders with SRK-439, a novel investigational myostatin inhibitor.
Presented new data supporting proof of concept for SRK-181 in heavily pretreated patients with resistant metastatic ccRCC.
Completed $98 million public offering, extending projected cash runway into second half of 2025.
Scholar Rock
Scholar Rock
Forward Guidance
Scholar Rock is focused on advancing its pipeline and expects the cash runway to extend well past the SAPPHIRE Phase 3 data readout in Q4 2024.
Positive Outlook
- Completing enrollment of the Phase 3 SAPPHIRE trial.
- Advancing SRK-439 into cardiometabolic disorders.
- Presenting new data supporting proof of concept for SRK-181.
- Completing $98 million public offering.
- Extending projected cash runway into second half of 2025.